HF
EVLO

HRT Financial’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

HRT Financial’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,413
Closed -$59K – 3750
2022
Q2 		$59K Buy
+1,413
New +$65.5K ﹤0.01% 2499

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's EVLO Position: Q3 2022 in Review

HRT Financial sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2022, closing a stake of 1,413 shares — an estimated $59K sold.

HRT Financial first reported a position in EVLO in Q2 2022 and held it in 1 quarter. The position peaked at $59K in Q2 2022. 41 funds tracked by Wall St. Rank hold EVLO as of Q3 2022.

  • HRT Financial reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • HRT Financial sold 1,413 Evelo Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $59K.
  • HRT Financial first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • HRT Financial's Evelo Biosciences, Inc. Common Stock position peaked at $59K in Q2 2022.
  • 41 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2022.

Based on HRT Financial's 13F filing for Q3 2022, filed 14 Nov 2022.